CATEGORY

Hydroxychloroquine

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Hydroxychloroquine.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Hydroxychloroquine Market Monitoring Dashboard


Price Trend
154000.00
Dec-2022
USD/MT
History Forecast
Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

Hydroxychloroquine Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Hydroxychloroquine category is 20.10%

Payment Terms

(in days)

The industry average payment terms in Hydroxychloroquine category for the current quarter is 54.3 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Hydroxychloroquine Suppliers


    253
    Total Suppliers
    8
    Diverse Suppliers
    68
    Normalized Supplier Rating
    Hydroxychloroquine Supplier

    Find the right-fit hydroxychloroquine supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    Catalent Inc.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    1
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    33

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    30
    Social
    26
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    34
    Human rights
    32
    Community Environment
    15
    Corporate governance
    56
    Human resources
    26
    Security Scorecard
    79

    Threat indicators
    A
    91
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    F
    52
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    D
    62
    Application Security
    Detecting common website application vulnerbilities
    A
    100
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    A
    100
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    90
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    catalent.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    0
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    0
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    0
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    0
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    21
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Hydroxychloroquine Market Intelligence

    global market outlook

      • The global Capacity of hydroxychloroquine (HCQ) is 150 MT in 2020 and is expected to grow with a CAGR of ~2 till 2024
      • India has accounted for nearly 70 percent of the global production of HCQ. Exports have increased drastically to cater to the global demand
      • Demand for HCQ has declined, as new drugs were invented for COVID-19, however, HCQ is always used to treat and manage a number of conditions, such as rheumatoid arthritis and the autoimmune disease called lupus
      • Raw materials, such as 4,7 DCQ and HNDA, account for more than 50–60 percent of the price of HCQ. This cost majorly determines the price of the final API/drug
      • Sci Pharmtech Inc., Ipca Laboratories Ltd., Cadila Healthcare Ltd., Fermion Oy, Chinoin Pharmaceutical, Amri Rensselaer Inc., Alkaloida Chemical Co. Zrt, Chongqing Kangle Pharmaceutical Co., Ltd., Laurus Labs Ltd., Srini Pharmaceuticals Private Ltd. And Mangalam Drugs are the key players in the market

    Hydroxychloroquine market report transcript


    Hydroxychloroquine Global Market Outlook:

    • India has accounted for nearly 70 percent of the global production of hydroxychloroquine. Exports have increased drastically to cater to the global demand
    • Demand for Hydroxychloroquine has declined, as new drugs were invented for COVID-19, however, HCQ is always used to treat and manage a number of conditions, such as rheumatoid arthritis and the autoimmune disease called lupus
    • Raw materials account for 50–60 percent of the total cost of production
    • HNDA and 4,7 DCQ are the major raw materials driving the production cost
    • Investing in capacity expansions and equipment are key fixed costs, which are involved in manufacturing of API

    Porter's Analysis on Hydroxychloroquine

    Supplier Power

    • Supplier power is medium, as the market is fragmented
    • Regulated players have more power, as there are only a few regulated players catering to the regulated markets

    Barriers to New Entrants

    • Availability of raw material is a major barrier to new suppliers entering the market

    Intensity of Rivalry

    • Market being fragmented, the intensity of rivalry is also high
    • Competition exists among certified manufacturers to supply HCQ to the developed markets

    Threat of Substitutes

    • Hydroxychloroquine, an anti-malarial drug, was initially used in the treatment of COVID-19, however, it was not very effective and had side effects
    • Several other vaccines are proving to be effective against COVID-19, hence, threat of substitute is high

    Buyer Power

    • Although several manufacturers are available in the market choosing a supplier, who has DMF or CEP approved suppliers is crucial
    • Buyer power is moderate, since the number of buyers in the market is also high